Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Oct 05, 2011	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 5	Bona fide gift	3,509	--	171,547
Dec 16, 2015	SCHLEIFER LEONARD S Director, President & CEO Trans History: 404	Director, President & CEO	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	172,723	--	172,723
Dec 16, 2014	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 628	Director, President Regeneron Laboratori	Form 4	Grant, award or other acquisition pursuant to Rule 16b-3(d)	172,723	--	172,723
Sep 17, 2003	YANCOPOULOS GEORGE Director, EVP, CSO, & Pres Regn Res Labs Trans History: 628	Director, EVP, CSO, & Pres Regn Res Labs	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	87,060	$4.25	172,948
Dec 19, 2007	VAGELOS P ROY Director Trans History: 742	Director	Form 4	Other acquisition or disposition	--	--	173,428
Jun 27, 2007	VAGELOS P ROY Director Trans History: 742	Director	Form 4	Other acquisition or disposition (describe transaction)	97,799	--	173,428
Sep 02, 2011	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Other acquisition or disposition	--	--	175,056
Jul 18, 2011	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Other acquisition or disposition	--	--	175,056
Jun 30, 2011	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Bona fide gift	3,798	--	175,056
Jul 13, 2011	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Open market or private sale of non-derivative or derivative security	10,438	$56.71	176,155

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media